[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 7 sources · 7 days · First seen · Last updated

Clinical development of diabetic foot infection treatments

Overview

Biotechnology companies are advancing clinical trials for topical gel treatments targeting diabetic foot infections and ulcers.

In Australia, Recce Pharmaceuticals has received ethics committee approval to expand its Phase 3 clinical trial for RECCE 327 Topical Gel (R327G). The expanded protocol includes a randomized, active-controlled study arm involving 208 patients to compare the gel against four physician-selected antibiotics. The trial also incorporates wound imaging via digital photography to provide objective measurements.

Concurrently, US-based Lakewood-Amedex Biotherapeutics is preparing for a Phase 2a clinical trial of Nu-3, a topical Bisphosphocin gel. This treatment is designed to combat infectious diseases and antibiotic-resistant bacterial strains by physically disrupting bacterial membranes.

Lakewood-Amedex was recently named a ‘Featured Company’ by B2i Digital, a designation intended to help the firm present its clinical programs and scientific milestones to a broader network of retail and institutional market participants.

Entities

Recce Pharmaceuticals · James Graham · Kelvin Cooper · B2i Digital, Inc. · Lakewood-Amedex Biotherapeutics Inc.

Timeline

  1. 18 days ago

    [BUSINESS] 4 sources
    Lakewood-Amedex Biotherapeutics named B2i Digital Featured Company

    Lakewood-Amedex Biotherapeutics has joined B2i Digital as a Featured Company to highlight its upcoming Phase 2a trial of Nu-3, a topical gel for treating infected diabetic foot ulcers.

  2. 24 days ago

    [HEALTH] 3 sources
    Recce Pharmaceuticals expands Phase 3 trial for diabetic foot infection gel

    Recce Pharmaceuticals has secured approval to expand its Phase 3 clinical trial for RECCE 327 Topical Gel, aiming to treat Diabetic Foot Infections through head-to-head comparisons with existing antibiotics.

Sources

finanzen.at · finanzen.ch · finnewsnetwork.com.au · kmsnews.org · sharecafe.com.au · smallcaps.com.au · techfinancials.co.za

This summary has been updated 1 time: see revision history